Jump to ratings and reviews
Rate this book

Cracking the Code: Understand and Profit from the Biotech Revolution That Will Transform Our Lives and Generate Fortunes

Rate this book
Everything you need to know about the most important trend in the history of the world

Within most people's lifetimes, the developments in the biotechnology sector will allow us to live increasingly long and healthy lives, as well as provide us with technological innovations that will transform the way we live. But these innovations offer more than just hope for a better life, but hope for better returns too. Financial returns of incredible magnitude await savvy investors and businesspeople who can see the massive changes on the horizon. This book details these fast-moving trends and innovations and offers extensive advice on how to profit from them in business and investing.

360 pages, Hardcover

First published April 20, 2012

6 people are currently reading
91 people want to read

About the author

Jim Mellon

11 books7 followers

Ratings & Reviews

What do you think?
Rate this book

Friends & Following

Create a free account to discover what your friends think of this book!

Community Reviews

5 stars
12 (30%)
4 stars
16 (41%)
3 stars
5 (12%)
2 stars
5 (12%)
1 star
1 (2%)
Displaying 1 - 3 of 3 reviews
Profile Image for Ken.
24 reviews3 followers
August 31, 2012
This is yet another good book in the futurology department. The authors start off letting you know that they have no official qualifications to be speaking on the topic of medical science and so fort. But then go on to reveal a good reason why you should listen to them nevertheless. They show you that they are extremely well read and learnt in this area, they have visited over 100 companies and talked to allot of scientist. They have read hundreds of articles, and books on the topic. It would seem that The authors Jim Mellon and Al Chalabi are truly autodidacts of the finest quality. It really shows later in their writing just how much they know on the topic

Now on the actual content of the book. The first half of the book gets rather scientific. Jim and Al explain to you the basic building blocks of life and how diseases is caused and so fort. They explain thins like what DNA is, what an element is and how it is defined. Some people (such as the science-phobes) may not particularly enjoy this section at all, but the authors really did it so that we could better understand. The way in which they wrote was also quite simple to grasp. I myself am a huge science fan, So I quite enjoyed it. But as I said, other investors may find this to be a bit of a turn of. The good news is that in my opinion, this was not absolutely necessary for you to understand the market. It would definitely give you some significant edge as an investor, but if you really can't stomach science then there is still much to be gained from this book by just skipping the first half and going directly into the investment situations that arise. The second half of the books is where they talk about the increase in health care leading to a uneven ratio of the elderly to the young and the disasters and changes in society it can lead to. They then recommend some remedies government should be considering and also companies you should pay attention to. They then wrap everything up with a summary at the end. It was quite a good book

The Verdict:
Very good book on the likely future of the investment landscape. The first half is gets more into explaining the mechanics of the medicine but then you get into the ways in which you can make money as an investor. I recommend purchasing

Physical Quality:
Very good quality all in all. the pages, the cover and the hardback are very good
237 reviews13 followers
May 6, 2013
Good compliment to Pelz' book on biotech options - Pelz book was focused on the options trading and mechanics of the biotech approval process while Mellon's book focused on active areas of research and some prognostication into the future based on current trends. I recommend both, although this book can become dated because it does integrate a lot of 'current status' of companies in 2012 which don't hold now as biotech is very volatile - some of the companies have crashed to penny stock status while others are bigger.
8 reviews
August 7, 2013
"We are living in the diamond age of discovery"
Fascinating overview of how biopharma and bio+med-tech shaping the future of the world and implications of the emerging global demographics with ageing populations.
Displaying 1 - 3 of 3 reviews

Can't find what you're looking for?

Get help and learn more about the design.